Clinical Trial Update: Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating AK1820 (isavuconazonium sulfate) for deep mycosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Mycosis

Drugs mentioned

• AK1820 (isavuconazonium sulfate)

Snippet

Sponsor: Asahi Kasei Therapeutics Corporation | Conditions: Deep Mycosis | Phase 3 | Status: COMPLETED